UTHR United Therapeutics
United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power of our brands, our entrepreneurial culture and our bioinformatics leadership. We also believe that our determination to be responsible citizens - having a positive impact on patients, the environment and society - will sustain our success in the long term. Through our wholly-owned subsidiary, Lung Biotechnology PBC, we are focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company.
Company profile
Ticker
UTHR
Exchange
Website
CEO
Martine Rothblatt
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
521984749
UTHR stock data
()
News
Stocks That Hit 52-Week Highs On Friday
9 Apr 21
JP Morgan Maintains Overweight on United Therapeutics, Raises Price Target to $212
8 Apr 21
48 Biggest Movers From Thursday
5 Apr 21
Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
2 Apr 21
12 Health Care Stocks Moving In Thursday's Intraday Session
1 Apr 21
Press releases
United Therapeutics Announces FDA Approval and Launch of Tyvaso® for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
1 Apr 21
United Therapeutics Corporation To Present At The 10th Annual J.P. Morgan Napa Valley Forum
24 Mar 21
United Therapeutics Corporation To Present At The Oppenheimer 31st Annual Healthcare Conference
9 Mar 21
United Therapeutics Corporation To Present At The 41st Annual Cowen Health Care Conference
24 Feb 21
United Therapeutics Corp. to Host Earnings Call
24 Feb 21
Calendar
24 Feb 21
12 Apr 21
31 Dec 21
Financial summary
Quarter (USD) |
Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Financial data from company earnings reports.
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 7 Apr 21 | Dwek Raymond | Common Stock | Sale back to company | Dispose D | No | Yes | 191.1 | 2,000 | 382.2K | 0 |
| 7 Apr 21 | Dwek Raymond | Common Stock | Option exercise | Aquire M | No | Yes | 54.77 | 2,000 | 109.54K | 2,000 |
| 7 Apr 21 | Dwek Raymond | Share Tracking Award Common Stock | Option exercise | Dispose M | No | Yes | 54.77 | 2,000 | 109.54K | 8,000 |
| 1 Apr 21 | Olian Judy D. | Common Stock | Sell | Dispose S | No | Yes | 184.96 | 4,207 | 778.13K | 5,790 |
| 1 Apr 21 | Olian Judy D. | Common Stock | Option exercise | Aquire M | No | Yes | 76.36 | 4,207 | 321.25K | 9,997 |
| 1 Apr 21 | Olian Judy D. | Stock Options Common Stock | Option exercise | Dispose M | No | Yes | 76.36 | 4,207 | 321.25K | 0 |
| 1 Apr 21 | Mahon Paul A | Common Stock | Sale back to company | Dispose D | No | Yes | 192.34 | 6,000 | 1.15M | 36,369 |
| 1 Apr 21 | Mahon Paul A | Common Stock | Option exercise | Aquire M | No | Yes | 94.96 | 6,000 | 569.76K | 42,369 |
| 1 Apr 21 | Mahon Paul A | Share Tracking Award Common Stock | Option exercise | Dispose M | No | Yes | 94.96 | 6,000 | 569.76K | 47,500 |
| 26 Mar 21 | Kurzweil Ray | Common Stock | Sale back to company | Dispose D | No | No | 171.21 | 3,750 | 642.04K | 7,540 |
Institutional ownership Q4 2020
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
95.8% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 348 |
| Opened positions | 68 |
| Closed positions | 45 |
| Increased positions | 97 |
| Reduced positions | 136 |
13F shares |
Current |
|---|---|
| Total value | 6.47B |
| Total shares | 42.56M |
| Total puts | 100.8K |
| Total calls | 246.9K |
| Total put/call ratio | 0.4 |
Largest owners |
Shares | Value |
|---|---|---|
| BLK Blackrock | 4.27M | $648.62M |
| Vanguard | 3.96M | $601.7M |
| Renaissance Technologies | 3.61M | $547.55M |
| Avoro Capital Advisors | 2.85M | $432.6M |
| FMR | 2.32M | $352.56M |
| STT State Street | 1.54M | $233.68M |
| Acadian Asset Management | 1.13M | $171.22M |
| Dimensional Fund Advisors | 886.33K | $134.53M |
| First Trust Advisors | 846.8K | $128.54M |
| Adage Capital Partners GP, L.L.C. | 825K | $125.23M |
Financial report summary
?Competition
Pfizer • Vivus • Actavis • Mannkind • FibroGen • Elbit Imaging • Arena Pharmaceuticals • Cumberland Pharmaceuticals • Insmed • PhaseBio PharmaceuticalsManagement Discussion
- This section of this Report generally discusses 2020, 2019, and 2018 items and year-to-year comparisons between 2020 and 2019. Discussions of year-to-year comparisons between 2019 and 2018 that are not included in this Report can be found in Part II, Item 7—Management’s Discussion and Analysis of Financial Condition and Results of Operations—Results of Operations of our Form 10-K filed on February 26, 2020 (our 2019 Annual Report).
- Net product sales from our treprostinil-based products (Remodulin, Tyvaso, and Orenitram) grew by $65.2 million in 2020, as compared to 2019. This increase was driven by growth in U.S. net product sales from our treprostinil-based products of $122.6 million in 2020, as compared to 2019, partially offset by a decline in net product sales outside the U.S. from our treprostinil-based products of $57.4 million, as compared to 2019.
- Remodulin net product sales decreased in 2020 as compared to 2019, driven by a $56.6 million decrease in sales outside the United States, primarily due to a decline in quantities sold, which we believe resulted from generic competition and the impact of COVID-19. U.S. Remodulin net product sales decreased by $13.7 million, as compared to 2019, which we believe primarily resulted from a reduction in new patient prescriptions and new patient starts that we experienced in the second quarter of 2020 due to the impact of COVID-19, as described above under Impact of COVID-19 on our Business.
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
abatacept, abundance, accessibility, acknowledging, add, Addressedthe, ADR, aggravate, ample, antifibrotic, aseptic, assignor, atmosphere, attain, Attorney, awaiting, back, belief, belumosudil, bidding, Biden, Biomedical, Biopharma, Biotech, Bipartisan, Boehringer, bone, borne, Brexit, Bristol, bulk, busy, bylaw, capability, capable, Carlo, caution, cautionary, CCPA, cellularize, Chancery, charitable, childcare, choice, CHP, Coalition, concomitant, conferencing, confirmed, Congressional, constantly, contact, Contractor, coordinating, copayment, COPD, cope, CorporationIndex, correlated, coupled, CRL, crucial, CVC, cybersecurity, Danyelza, de, deadline, decade, declassification, DEI, Denko, diagnostic, dismissed, disproportionate, diversification, Dohme, downturn, DPI, duty, economy, Emerging, endorsement, England, enjoined, enrich, Esbriet, estoppel, ethnic, exacerbated, excellence, exiting, exponential, extinguish, Facebook, FCP, FDASIA, FDCA, feel, feeling, Ferrer, FibroGen, fibrosing, fibrotic, field, fifteen, fILD, firmly, footnote, forum, foster, freight, FSS, fullest, FVC, Galecto, GDPR, GmbH, great, Grupo, hall, hard, heightened, hindered, HIPAA, Holistic, home, HRSA, Humana, hypersensitivity, identification, IIP, ILD, imputation, inapplicable, incident, incomplete, indefinite, Ingelheim, inOur, instilled, instrument, intact, interact, Internacional, ISR, Journal, judge, justify, Kadmon, landscape, language, Latin, lessen, Liminal, Linda, lodge, LP, malfunction, malfunctioned, marketplace, marrow, Maxwell, MDRP, MediciNova, mental, Merck, misreporting, misrepresentation, missing, mission, Monte, mounting, moved, MSP, MSPA, Neck, nintedanib, Nitto, nonclinical, novo, nurse, nursing, NV, ofEquity, Ofev, ofthe, omitted, Orencia, overcharge, overcharging, overcome, overshadow, owed, palmitil, pamrevlumab, pandemic, passion, passionately, pause, paused, peer, Pemziviptadil, pervasive, pirfenidone, PMPI, precautionary, precipitate, prepay, prevalent, prioritization, prioritized, proactive, proud, purification, purported, pursuit, qui, racial, Racketeer, Radford, rapidly, recalculate, recalculation, recombinant, recommenced, recordkeeping, recoup, recruit, recruiting, recruitment, regular, remanded, repeated, repurpose, resource, resume, retroactive, rewrite, rigorously, RLD, robust, safeguarding, safest, segregated, sense, sequestration, Seralutinib, Sharpe, shielding, shut, simulation, situation, SK, smart, sNDA, solid, sonic, speak, specialist, Speed, Squibb, steadily, stringent, strive, strongly, Sumitovant, sunset, Sunshine, supervisory, Surgeon, surveillance, tam, Task, telemedicine, TETON, thereunder, thrive, tipelukast, today, top, town, TPIP, transportation, travel, Tricare, Turkey, turnover, ultra, unaffected, unannounced, unclassified, unconsolidated, unconstitutional, undergone, undermine, undertaken, undisclosed, UnitedHealth, Unitherian, unprecedented, unpredictable, untitled, VA, vaccine, Veteran, vial, VirginiaFebruary, visit, vital, waiting, waived, Warp, Wisconsin, Women, workforce, workplace, worth, Zone
Removed:
AB, acceleration, accident, admission, aggressively, ASR, attracting, authorizing, Bardoxolone, borrowing, CEO, chest, chose, Citibank, companywide, compound, concession, consulting, continually, convertible, counterparty, crystal, DB, debarment, declared, departed, depot, desired, Deutsche, devote, disgorgement, donut, drop, dynamic, engineered, enhance, estate, familiarized, favor, forfeiture, fulfilled, gel, harming, hole, implied, incremental, incrementally, introduce, investigated, jointly, Junior, leukoencephalopathy, London, mandatorily, Mark, narrow, negotiate, noncompetitive, observe, obsolete, overseeing, porcine, posterior, promised, real, Reata, reclassify, redeemable, redemption, render, repaid, repealed, requesting, retaining, scrutinizing, skilled, staggered, strike, subjecting, subpoena, succession, transverse, Unaudited, unaware, unfavorably, urinary, validate, vein, viability
Financial reports
10-K
2020 FY
Annual report
24 Feb 21
10-Q
2020 Q3
Quarterly report
28 Oct 20
10-Q
2020 Q2
Quarterly report
29 Jul 20
10-Q
2020 Q1
Quarterly report
29 Apr 20
10-K
2019 FY
Annual report
26 Feb 20
10-Q
2019 Q3
Quarterly report
30 Oct 19
10-Q
2019 Q2
Quarterly report
31 Jul 19
10-Q
2019 Q1
Quarterly report
1 May 19
10-K
2018 FY
Annual report
27 Feb 19
10-Q
2018 Q3
Quarterly report
31 Oct 18
Current reports
8-K
Other Events
1 Apr 21
8-K
Other Events
3 Mar 21
8-K
United Therapeutics Corporation Reports Fourth Quarter
24 Feb 21
8-K
United Therapeutics Announces Commercial Launch
10 Feb 21
8-K
Amendments to Articles of Incorporation or Bylaws
5 Feb 21
8-K
United Therapeutics Announces Breeze Study of
28 Jan 21
8-K
Other Events
22 Jan 21
8-K
Other Events
13 Jan 21
8-K
United Therapeutics Announces Agreement to Acquire Priority Review Voucher
28 Dec 20
8-K
Phase 3 TETON study planned in 2021 for Tyvaso® in patients with idiopathic pulmonary fibrosis
9 Dec 20
Registration and prospectus
S-8
Registration of securities for employees
29 Jul 20
S-8
Registration of securities for employees
31 Jul 19
S-8
Registration of securities for employees
1 Mar 19
S-8
Registration of securities for employees
28 Jun 18
S-8
Registration of securities for employees
28 Jun 15
S-8
Registration of securities for employees
28 Jul 14
S-8
Registration of securities for employees
29 Apr 13
S-8
Registration of securities for employees
25 Jul 12
S-8 POS
Registration of securities for employees (post-effective amendment)
27 Feb 12
S-8
Registration of securities for employees
27 Feb 12
Proxies
DEFA14A
Additional proxy soliciting materials
15 Jun 20
DEFA14A
Additional proxy soliciting materials
29 Apr 20
DEF 14A
Definitive proxy
29 Apr 20
PRE 14A
Preliminary proxy
13 Apr 20
DEFA14A
Additional proxy soliciting materials
17 Jun 19
DEF 14A
Definitive proxy
29 Apr 19
DEFA14A
Additional proxy soliciting materials
22 May 18
DEF 14A
Definitive proxy
26 Apr 18
DEF 14A
Definitive proxy
27 Apr 17
DEF 14A
Definitive proxy
27 Apr 16
Other
UPLOAD
Letter from SEC
29 Dec 20
CORRESP
Correspondence with SEC
22 Dec 20
UPLOAD
Letter from SEC
14 Dec 20
SD
Conflict minerals disclosure
1 Jun 20
SD
Conflict minerals disclosure
29 May 19
CT ORDER
Confidential treatment order
21 Mar 19
CT ORDER
Confidential treatment order
20 Mar 19
SD
Conflict minerals disclosure
31 May 18
CT ORDER
Confidential treatment order
14 Mar 18
SD
Conflict minerals disclosure
25 May 17
Ownership
4
UNITED THERAPEUTICS / RAYMOND DWEK ownership change
8 Apr 21
4
UNITED THERAPEUTICS / PAUL A MAHON ownership change
2 Apr 21
4
UNITED THERAPEUTICS / Judy D. Olian ownership change
2 Apr 21
4
UNITED THERAPEUTICS / RAY KURZWEIL ownership change
29 Mar 21
4
UNITED THERAPEUTICS / PAUL A MAHON ownership change
19 Mar 21
4
UNITED THERAPEUTICS / Judy D. Olian ownership change
19 Mar 21
4/A
UNITED THERAPEUTICS / PAUL A MAHON ownership change
16 Mar 21
4/A
UNITED THERAPEUTICS / JAMES EDGEMOND ownership change
16 Mar 21
4/A
UNITED THERAPEUTICS / MARTINE A ROTHBLATT ownership change
16 Mar 21
4/A
UNITED THERAPEUTICS / MICHAEL BENKOWITZ ownership change
16 Mar 21
Patents
GRANT
Utility
Extracellular vesicles with enhanced potency
16 Mar 21
Provided are methods for isolating potent extracellular vesicle or exosome populations from mesenchymal stromal cells, and the use of the isolated extracellular vesicles or exosomes in treating vasculopathy, including pulmonary hypertension, bronchopulmonary dysplasia, and disease and conditions associated with mitochondrial dysfunction.
GRANT
Utility
Compounds and methods for delivery of prostacyclin analogs
16 Mar 21
This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis.
APP
Utility
Methods and Compositions for Culturing Alveolar Cells
4 Mar 21
Described herein are methods and compositions for use in expanding alveolar epithelial cells.
APP
Utility
Pre-conditioned Extracellular Vesicles and Methods of Production
25 Feb 21
A method for treating inflammatory diseases is provided.
APP
Utility
Treprostinil Prodrugs
25 Feb 21
Provided are novel prodrugs of treprostinil, as well as methods of making and methods of using these prodrugs.
Transcripts
2020 Q4
Earnings call transcript
24 Feb 21
2020 Q3
Earnings call transcript
28 Oct 20
2020 Q2
Earnings call transcript
29 Jul 20
2020 Q1
Earnings call transcript
29 Apr 20
2019 Q4
Earnings call transcript
26 Feb 20
2019 Q3
Earnings call transcript
30 Oct 19
2019 Q2
Earnings call transcript
31 Jul 19
2019 Q1
Earnings call transcript
1 May 19
2018 Q4
Earnings call transcript
27 Feb 19
2018 Q3
Earnings call transcript
31 Oct 18
Reddit threads
In-depth DD on Bio Stock Nearing Approval of Breakthrough Drug to Treat Depression: Axsome Therapeutics (AXSM)
12 Apr 21
In-depth DD on Bio Stock Nearing Approval of Breakthrough Drug to Treat Depression: Axsome Therapeutics (AXSM)
12 Apr 21
Here is a Market Recap for today Thursday, April 8, 2021
8 Apr 21
Here is a Market Recap for today Thursday, April 8, 2021
8 Apr 21
U.S. Market Recap - Thursday, April 1, 2021
1 Apr 21
The Only Game Plan April 1, 2021
1 Apr 21
Company Earnings for 15 to 19 March 2021
14 Mar 21
Expected Biotech News 15 to 23 March 2021 and PDUFA List 21 March to 28 April 2021
14 Mar 21
Expected Biotech News 15 to 23 March 2021 and PDUFA List 21 March to 28 April 2021
14 Mar 21
Equity Idea - UTHR PT 195 SOTP Based
1 Mar 21